Biltmore Family Office’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $905K | Sell |
1,804
-205
| -10% | -$98.4K | 0.12% | 124 |
|
|
2026
Q1 | $988K | Buy |
2,009
+21
| +1% | +$11.4K | 0.14% | 105 |
|
|
2025
Q4 | $1.15M | Buy |
1,988
+407
| +26% | +$230K | 0.16% | 93 |
|
|
2025
Q3 | $767K | Buy |
1,581
+61
| +4% | +$28.4K | 0.11% | 110 |
|
|
2025
Q2 | $617K | Buy |
1,520
+1
| +0.1% | +$418 | 0.1% | 114 |
|
|
2025
Q1 | $757K | Hold |
1,519
| – | – | 0.13% | 100 |
|
|
2024
Q4 | $791K | Hold |
1,519
| – | – | 0.13% | 96 |
|
|
2024
Q3 | $940K | Sell |
1,519
-13
| -0.8% | -$7.7K | 0.16% | 88 |
|
|
2024
Q2 | $848K | Buy |
1,532
+5
| +0.3% | +$2.86K | 0.16% | 86 |
|
|
2024
Q1 | $888K | Buy |
1,527
+53
| +4% | +$29.7K | 0.18% | 84 |
|
|
2023
Q4 | $783K | Buy |
1,474
+27
| +2% | +$13.1K | 0.16% | 88 |
|
|
2023
Q3 | $733K | Hold |
1,447
| – | – | 0.17% | 84 |
|
|
2023
Q2 | $755K | Sell |
1,447
-1,144
| -44% | -$617K | 0.16% | 86 |
|
|
2023
Q1 | $1.49M | Sell |
2,591
-1
| -0% | -$564 | 0.32% | 53 |
|
|
2022
Q4 | $1.43M | Buy |
2,592
+1,144
| +79% | +$606K | 0.29% | 51 |
|
|
2022
Q3 | $735K | Buy |
1,448
+1
| +0.1% | +$560 | 0.17% | 78 |
|
|
2022
Q2 | $787K | Hold |
1,447
| – | – | 0.2% | 81 |
|
|
2022
Q1 | $855K | Sell |
1,447
-798
| -36% | -$458K | 0.18% | 83 |
|
|
2021
Q4 | $1.5M | Hold |
2,245
| – | – | 0.29% | 57 |
|
|
2021
Q3 | $1.28M | Buy |
2,245
+796
| +55% | +$437K | 0.31% | 55 |
|
|
2021
Q2 | $731K | Buy |
1,449
+44
| +3% | +$20.8K | 0.21% | 80 |
|
|
2021
Q1 | $642K | Hold |
1,405
| – | – | 0.2% | 76 |
|
|
2020
Q4 | $655K | Hold |
1,405
| – | – | 0.2% | 73 |
|
|
2020
Q3 | $621K | Hold |
1,405
| – | – | 0.35% | 65 |
|
|
2020
Q2 | $509K | Hold |
1,405
| – | – | 0.31% | 79 |
|
|
2020
Q1 | $399K | Hold |
1,405
| – | – | 0.26% | 92 |
|
|
2019
Q4 | $457K | Buy |
1,405
+22
| +2% | +$6.67K | 0.18% | 101 |
|
|
2019
Q3 | $403K | Buy |
1,383
+11
| +0.8% | +$3.15K | 0.17% | 110 |
|
|
2019
Q2 | $403K | Hold |
1,372
| – | – | 0.22% | 95 |
|
|
2019
Q1 | $376K | Hold |
1,372
| – | – | 0.19% | 107 |
|
|
2018
Q4 | $307K | Hold |
1,372
| – | – | 0.17% | 114 |
|
|
2018
Q3 | $335K | Hold |
1,372
| – | – | 0.16% | 114 |
|
|
2018
Q2 | $284K | Hold |
1,372
| – | – | 0.14% | 119 |
|
|
2018
Q1 | $283K | Hold |
1,372
| – | – | 0.13% | 133 |
|
|
2017
Q4 | $261K | Buy |
+1,372
| New | +$263K | 0.12% | 136 |
|
Other funds holding TMO
Biltmore Family Office's TMO Position: Q2 2026 in Review
Biltmore Family Office reduced its Thermo Fisher Scientific (TMO) stake by 10% in Q2 2026, selling an estimated $98.4K and leaving 1,804 shares worth $905K. The position accounts for 0.12% of the portfolio, ranked #124.
Biltmore Family Office first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.5M in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Biltmore Family Office held 1,804 shares of Thermo Fisher Scientific worth $905K as of Q2 2026.
- Biltmore Family Office sold 205 Thermo Fisher Scientific shares in Q2 2026, an estimated $98.4K.
- Thermo Fisher Scientific made up 0.12% of Biltmore Family Office's portfolio in Q2 2026, its #124 holding.
- Biltmore Family Office first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
- Biltmore Family Office's Thermo Fisher Scientific position peaked at $1.5M in Q4 2021.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Biltmore Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.